Company profile for Alfred E Tiefenbacher GmbH

PharmaCompass

We are the TIEFENBACHER GROUP, Health Pioneers since 1963.

Related CompaniesRelated Companies

About

As a key component of the TIEFENBACHER GROUP, a 100% family-owned leader in healthcare, we offer comprehensive solutions across the entire life cycle of pharmaceutical products. Our expertise spans the development, manufacturing, and registration of generic, value-added, and innovative medicines, along with e-health solutions tailored for our B2B clients & distribution partners. Trusted globally, our outstanding capabilities in crafting top-tier dossiers and managing intricate product launches in over 80 countries. Our in-house laboratories and manufacturing facilities in India and Cyprus enable us to establish efficient supply chains.

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Van-der-Smissen-Strasse 1, 22767 Hamburg
Telephone
Telephone
+49 404418090
Client Website
Website
youtube
YouTube
Twitter
Twitter
Contact Info
Others

Events

Webinars & Exhibitions

Default Event

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content read-more

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-api-ingredients-gmbh-party-content-89424.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-21386.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-api-ingredients-gmbh-party-content-96648.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-api-ingredients-gmbh-party-content-97507.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-api-ingredients-gmbh-party-content-987.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-26459.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-7484.pdf

NEWS #PharmaBuzz

read-more
read-more

https://tiefenbacher-pharmaceuticals.com/2024/05/08/tiefenbacher-api-ingredients-offers-custom-synthesis-of-intermediates-apis/

PRESS RELEASE
08 May 2024

https://tiefenbacher-pharmaceuticals.com/2024/05/02/tiefenbacher-group-renovation-of-headquarters-in-hamburg/

PRESS RELEASE
02 May 2024

https://tiefenbacher-pharmaceuticals.com/2024/04/09/tiefenbacher-first-to-market-launch-rivaroxaban/

PRESS RELEASE
09 Apr 2024

https://tiefenbacher-pharmaceuticals.com/2024/04/08/tiefenbacher-group-welcomes-new-coo-sandip-tarate/

PRESS RELEASE
08 Apr 2024

https://tiefenbacher-pharmaceuticals.com/2024/03/19/tiefenbacher-group-awarded-ecovadis-silver-medal/

PRESS RELEASE
19 Mar 2024

https://tiefenbacher-pharmaceuticals.com/2024/02/29/tiefenbacher-group-on-awareness-for-rare-disease-day/

PRESS RELEASE
29 Feb 2024

Drugs in Development

read-more
read-more

Details:

Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


Lead Product(s): Rivaroxaban

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Xarelto-Generic

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 09, 2024

Tiefenbacher Compnay Banner

01

OPRD USA
Not Confirmed

Lead Product(s) : Rivaroxaban

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

Product Name : Xarelto-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

April 09, 2024

Tiefenbacher Compnay Banner

Details:

Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


Lead Product(s): Rivaroxaban

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Xarelto-Generic

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 16, 2023

Tiefenbacher Compnay Banner

02

OPRD USA
Not Confirmed

Lead Product(s) : Rivaroxaban

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

Product Name : Xarelto-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

November 16, 2023

Tiefenbacher Compnay Banner

Details:

Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.


Lead Product(s): Teriflunomide

Therapeutic Area: Neurology Brand Name: Aubagio-Generic

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 27, 2023

Tiefenbacher Compnay Banner

03

OPRD USA
Not Confirmed

Lead Product(s) : Teriflunomide

Therapeutic Area : Neurology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Product Name : Aubagio-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

September 27, 2023

Tiefenbacher Compnay Banner

Details:

Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.


Lead Product(s): Bilastine

Therapeutic Area: Immunology Brand Name: Bilastine Tiefenbacher

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 14, 2023

Tiefenbacher Compnay Banner

04

OPRD USA
Not Confirmed

Lead Product(s) : Bilastine

Therapeutic Area : Immunology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.

Product Name : Bilastine Tiefenbacher

Product Type : Small molecule

Upfront Cash : Not Applicable

March 14, 2023

Tiefenbacher Compnay Banner

Details:

Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.


Lead Product(s): Apremilast

Therapeutic Area: Dermatology Brand Name: Otezla-Generic

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 01, 2022

Tiefenbacher Compnay Banner

05

OPRD USA
Not Confirmed

Lead Product(s) : Apremilast

Therapeutic Area : Dermatology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.

Product Name : Otezla-Generic

Product Type : HPAPI

Upfront Cash : Inapplicable

December 01, 2022

Tiefenbacher Compnay Banner

Details:

Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.


Lead Product(s): Abiraterone Acetate,Prednisolone

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 17, 2022

Tiefenbacher Compnay Banner

06

OPRD USA
Not Confirmed

Lead Product(s) : Abiraterone Acetate,Prednisolone

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

November 17, 2022

Tiefenbacher Compnay Banner

Details:

Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.


Lead Product(s): Apixaban

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Apixaban Tiefenbacher

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 20, 2022

Tiefenbacher Compnay Banner

07

OPRD USA
Not Confirmed

Lead Product(s) : Apixaban

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Product Name : Apixaban Tiefenbacher

Product Type : HPAPI

Upfront Cash : Inapplicable

October 20, 2022

Tiefenbacher Compnay Banner

Details:

Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.


Lead Product(s): Vildagliptin,Metformin

Therapeutic Area: Endocrinology Brand Name: Vildagliptin-Metformin-Generic

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 08, 2022

Tiefenbacher Compnay Banner

08

OPRD USA
Not Confirmed

Lead Product(s) : Vildagliptin,Metformin

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.

Product Name : Vildagliptin-Metformin-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

September 08, 2022

Tiefenbacher Compnay Banner

Details:

Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


Lead Product(s): Rivaroxaban

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Xarelto-Generic

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2022

Tiefenbacher Compnay Banner

09

OPRD USA
Not Confirmed

Lead Product(s) : Rivaroxaban

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

Product Name : Xarelto-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

July 15, 2022

Tiefenbacher Compnay Banner

Details:

Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.


Lead Product(s): Teriflunomide

Therapeutic Area: Immunology Brand Name: Teriflunomide-Generic

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

Tiefenbacher Compnay Banner

10

OPRD USA
Not Confirmed

Lead Product(s) : Teriflunomide

Therapeutic Area : Immunology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.

Product Name : Teriflunomide-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

June 01, 2022

Tiefenbacher Compnay Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

Europe

read-more
read-more

01

Brand Name : N/A

Regulatory Info : EU Dossier Readiness-Q...

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Dosage Strength : 250MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : EU Dossier Readiness-Q...

Registration Country : Germany

Tiefenbacher Compnay Banner

02

Brand Name : N/A

Regulatory Info : EU Dossier Readiness-Q...

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Dosage Strength : 500MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : EU Dossier Readiness-Q...

Registration Country : Germany

Tiefenbacher Compnay Banner

03

Brand Name : N/A

Regulatory Info : Status- Under Registra...

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Film Coated Tablet

Dosage Strength : 5MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : Status- Under Registra...

Registration Country : Germany

Tiefenbacher Compnay Banner

04

Brand Name : N/A

Regulatory Info : Status- Under Registra...

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Film Coated Tablet

Dosage Strength : 10MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : Status- Under Registra...

Registration Country : Germany

Tiefenbacher Compnay Banner

05

Brand Name : N/A

Regulatory Info : Registered in EU

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Film Coated Tablet

Dosage Strength : 1MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : Registered in EU

Registration Country : Germany

Tiefenbacher Compnay Banner

06

Brand Name : N/A

Regulatory Info : Registered in EU

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Dosage Strength : 5MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : Registered in EU

Registration Country : Germany

Tiefenbacher Compnay Banner

07

Brand Name : N/A

Regulatory Info : Registered in EU

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Dosage Strength : 10MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : Registered in EU

Registration Country : Germany

Tiefenbacher Compnay Banner

08

Brand Name : N/A

Regulatory Info : Registered in EU

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Dosage Strength : 15MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : Registered in EU

Registration Country : Germany

Tiefenbacher Compnay Banner

09

Brand Name : N/A

Regulatory Info : EU Dossier Readiness-Q...

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Dosage Strength : 2.5MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : EU Dossier Readiness-Q...

Registration Country : Germany

Tiefenbacher Compnay Banner

10

Brand Name : N/A

Regulatory Info : EU Dossier Readiness-Q...

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Dosage Strength : 5MG

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info : EU Dossier Readiness-Q...

Registration Country : Germany

Tiefenbacher Compnay Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

Brand Name : N/A

Regulatory Info : EU Dossier Readiness-Q1 2019

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Brand Name :

Dosage Strength : 250MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : EU Dossier Readiness-Q1 2019

Registration Country : Germany

Tiefenbacher Compnay Banner

02

Brand Name : N/A

Regulatory Info : EU Dossier Readiness-Q1 2019

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Brand Name :

Dosage Strength : 500MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : EU Dossier Readiness-Q1 2019

Registration Country : Germany

Tiefenbacher Compnay Banner

03

Brand Name : N/A

Regulatory Info : Status- Under Registration

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Film Coated Tablet

Brand Name :

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Status- Under Registration

Registration Country : Germany

Tiefenbacher Compnay Banner

04

Brand Name : N/A

Regulatory Info : Status- Under Registration

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Film Coated Tablet

Brand Name :

Dosage Strength : 10MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Status- Under Registration

Registration Country : Germany

Tiefenbacher Compnay Banner

05

Brand Name : N/A

Regulatory Info : Registered in EU

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Film Coated Tablet

Brand Name :

Dosage Strength : 1MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Registered in EU

Registration Country : Germany

Tiefenbacher Compnay Banner

06

Brand Name : N/A

Regulatory Info : Registered in EU

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Brand Name :

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Registered in EU

Registration Country : Germany

Tiefenbacher Compnay Banner

07

Brand Name : N/A

Regulatory Info : Registered in EU

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Brand Name :

Dosage Strength : 10MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Registered in EU

Registration Country : Germany

Tiefenbacher Compnay Banner

08

Brand Name : N/A

Regulatory Info : Registered in EU

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Brand Name :

Dosage Strength : 15MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Registered in EU

Registration Country : Germany

Tiefenbacher Compnay Banner

09

Brand Name : N/A

Regulatory Info : EU Dossier Readiness-Q4 2018

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Brand Name :

Dosage Strength : 2.5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : EU Dossier Readiness-Q4 2018

Registration Country : Germany

Tiefenbacher Compnay Banner

10

Brand Name : N/A

Regulatory Info : EU Dossier Readiness-Q4 2018

Registration Country : Germany

Alfred E Tiefenbacher GmbH

Dosage Form : Tablet

Brand Name :

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : EU Dossier Readiness-Q4 2018

Registration Country : Germany

Tiefenbacher Compnay Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Check the inspections & registration from this company

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty